Gastroenterology-Urology Devices; Reclassification of Diagnostic Endoscopic Light Source Systems To Be Renamed Cystoscopic Systems Intended as an Aid for Detection of Bladder Cancer
Key claim: FDA proposes moving certain cystoscopic light-source systems used to help detect bladder cancer from the strictest premarket-approval pathway into class II with special controls and 510(k) notification, and creating a matching device classification regulation.
Abstract
(Proposed Rule · Health and Human Services Department, Food and Drug Administration) The Food and Drug Administration (FDA) is proposing to reclassify diagnostic endoscopic light source systems (product code OAY), which are postamendments class III devices, from class III (premarket approval) into class II (special controls), subject to premarket notification. FDA is also proposing a new device classification regulation with the name “Cystoscopic system intended as an aid for detection of bladder cancer,” along with special controls that FDA believes are necessary to provide a reasonable assurance of the safety and effectiveness of these devices.
Why this matters
Reclassification from Class III to Class II lowers the regulatory barrier for cystoscopic bladder-cancer detection aids, replacing premarket approval with 510(k) review plus special controls. For manufacturers this can shorten time-to-market and reduce costs, and for urology providers and patients it could expand availability of these diagnostic tools while shifting FDA’s safety assurance to design and labeling controls rather than case-by-case PMA review.